Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT

NCT02635035 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Attention Deficit Disorder
Attention Deficit Hyperactivity Disorder

Interventions

DRUG: Lisdexamfetamine
DRUG: Placebo

Sponsor

NYU Langone Health

Collaborators

[object Object]